准NLRP3炎症酶消除了免疫检查点阻断剂的心脏毒性
Yang Lu1,2,3,4, Jiamin Gao1,2,3,4, Yachen Hou1,2,3,4
1Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Journal for immunotherapy of cancer
|January 8, 2025
概括
使用MCC950阻断NLRP3炎症酶会降低免疫检查点抑制剂心脏毒性. 这种方法可以改善心脏功能,增强抗瘤免疫力,为癌症患者提供双重好处.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂 (ICI) 是重要的癌症疗法,但由于超免疫激活,可能导致心脏毒性.
- 目前ICI诱导心脏毒性的治疗方法有限,可能会损害抗瘤反应.
研究的目的:
- 确定能缓解ICI诱导心脏毒性的策略,同时保持或增强抗瘤免疫力.
- 研究NLRP3炎症酶在ICI相关心脏毒性的作用及其治疗潜力.
主要方法:
- 使用一种与ICI治疗的黑色素瘤小鼠模型来诱导心脏毒性.
- 用MCC950抑制NLRP3炎症酶的活性.
- 评估心脏功能,免疫细胞概况和基因表达,使用心声学,流细胞计和RNA测序.
主要成果:
- 使用MCC950抑制NLRP3显著减少心脏炎症和改善心脏功能.
- MCC950治疗抑制了瘤生长并促进了瘤回归,即使在已确定的心脏毒性中也是如此.
- 单细胞RNA测序揭示了心脏中MCC950调节的免疫细胞种群,减少了致病细胞,增加了修复性细胞.
结论:
- 抑制NLRP3炎症酶是一种有前途的策略,用于控制ICI诱导的心脏毒性.
- 这种方法有效地将抗瘤疗效与心脏毒性副作用分开,提供了一种新的治疗途径.
相关概念视频
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114